Michael S Ominsky
Overview
Explore the profile of Michael S Ominsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
3874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glorieux F, Langdahl B, Chapurlat R, De Beur S, Sutton V, Poole K, et al.
J Bone Miner Res
. 2024 Jul;
39(9):1215-1228.
PMID: 39012717
Osteogenesis imperfecta (OI) is a rare genetic disorder commonly caused by variants of the type I collagen genes COL1A1 and COL1A2. OI is associated with increased bone fragility, bone deformities,...
2.
Rejnmark L, Gosmanova E, Khan A, Makita N, Imanishi Y, Takeuchi Y, et al.
Adv Ther
. 2024 May;
41(6):2500-2518.
PMID: 38691316
Introduction: Individuals with chronic hypoparathyroidism managed with conventional therapy (active vitamin D and calcium) have an increased risk for renal dysfunction versus age- and sex-matched controls. Treatments that replace the...
3.
Florio M, Kostenuik P, Stolina M, Asuncion F, Grisanti M, Ke H, et al.
J Bone Joint Surg Am
. 2023 May;
105(15):1145-1155.
PMID: 37159527
Background: Fracture repair involves the reactivation of developmental signaling cascades, including Wnt signaling that stimulates bone formation and bone regeneration. Rodent data indicate that dual inhibition of the Wnt signaling...
4.
Cardinal M, Chretien A, Roels T, Lafont S, Ominsky M, Devogelaer J, et al.
Front Genet
. 2021 Aug;
12:705505.
PMID: 34447412
Osteogenesis imperfecta (OI), which is most often due to a collagen type 1 gene mutation, is characterized by low bone density and bone fragility. In OI patients, gender-related differences were...
5.
Arlt H, Besschetnova T, Ominsky M, Fredericks D, Lanske B
JOR Spine
. 2021 Mar;
4(1):e1132.
PMID: 33778406
Background: Abaloparatide is a parathyroid hormone receptor agonist that increases bone formation and reduces vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis. Animal studies indicate abaloparatide stimulates vertebral...
6.
Dempster D, Zhou H, Rao S, Recknor C, Miller P, Leder B, et al.
J Bone Miner Res
. 2021 Jan;
36(4):644-653.
PMID: 33434314
Anabolic osteoporosis drugs improve bone mineral density by increasing bone formation. The objective of this study was to evaluate the early effects of abaloparatide on indices of bone formation and...
7.
Arlt H, Mullarkey T, Hu D, Baron R, Ominsky M, Mitlak B, et al.
Bone Rep
. 2020 Jul;
13:100291.
PMID: 32637467
Intermittent administration of PTH type 1 receptor (PTH1R) agonists increases bone remodeling, with greater stimulation of bone formation relative to bone resorption causing net gains in bone mass. This pharmacodynamic...
8.
Cardinal M, Dessain A, Roels T, Lafont S, Ominsky M, Devogelaer J, et al.
Calcif Tissue Int
. 2020 Feb;
106(5):494-508.
PMID: 32025752
In osteogenesis imperfecta (OI), vertebrae brittleness causes thorax deformations and leads to cardiopulmonary failure. As sclerostin-neutralizing antibodies increase bone mass and strength in animal models of osteoporosis, their administration in...
9.
Cardinal M, Tys J, Roels T, Lafont S, Ominsky M, Devogelaer J, et al.
Bone
. 2019 May;
124:137-147.
PMID: 31051315
Osteogenesis imperfecta type III (OI) is a serious genetic condition with poor bone quality and a high fracture rate in children. In a previous study, it was shown that a...
10.
Taylor S, Hu R, Pacheco E, Locher K, Pyrah I, Ominsky M, et al.
Bone Rep
. 2018 Jun;
8:95-103.
PMID: 29955627
Inhibition of sclerostin with sclerostin antibody (Scl-Ab) results in stimulation of bone formation on cancellous (Cn), endocortical (Ec), and periosteal (Ps) surfaces in rodents and non-human primates. With long-term dosing...